tetano
Editor, Senior Moderator
Sci Rep
. 2024 Mar 5;14(1):5430.
doi: 10.1038/s41598-024-56195-y. Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge
Supavit Chesdachai[SUP] 1 [/SUP], Christina G Rivera[SUP] 2 [/SUP], Kristin C Cole[SUP] 3 [/SUP], Hilary R Teaford[SUP] 2 [/SUP], Maria L Gonzalez Suarez[SUP] 4 [/SUP], Jennifer J Larsen[SUP] 5 [/SUP], Ravindra Ganesh[SUP] 6 [/SUP], Sidna Tulledge-Scheitel[SUP] 7 [/SUP], Raymund R Razonable[SUP] 8 [/SUP]
Affiliations
Studies conducted prior to SARS-CoV-2 Omicron demonstrated that sotrovimab and remdesivir reduced hospitalization among high-risk outpatients with mild to moderate COVID-19. However, their effectiveness has not been directly compared. This study examined all high-risk outpatients with mild to moderate COVID-19 who received either remdesivir or sotrovimab at Mayo Clinic during the Omicron BA.1 surge from January to March 2022. COVID-19-related hospitalization or death within 28 days were compared between the two treatment groups. Among 3257 patients, 2158 received sotrovimab and 1099 received remdesivir. Patients treated with sotrovimab were younger and had lower comorbidity but were more likely to be immunocompromised than remdesivir-treated patients. The majority (89%) had received at least one dose of COVID-19 vaccine. COVID-19-related hospitalization (1.5% and 1.0% in remdesivir and sotrovimab, respectively, p = .15) and mortality within 28 days (0.4% in both groups, p = .82) were similarly low. A propensity score weighted analysis demonstrated no significant difference in the outcomes between the two groups. We demonstrated favorable outcomes that were not significantly different between patients treated with remdesivir or sotrovimab.
Keywords: COVID-19; Outcome; Remdesivir; SARS-2-CoV; Sotrovimab.
. 2024 Mar 5;14(1):5430.
doi: 10.1038/s41598-024-56195-y. Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge
Supavit Chesdachai[SUP] 1 [/SUP], Christina G Rivera[SUP] 2 [/SUP], Kristin C Cole[SUP] 3 [/SUP], Hilary R Teaford[SUP] 2 [/SUP], Maria L Gonzalez Suarez[SUP] 4 [/SUP], Jennifer J Larsen[SUP] 5 [/SUP], Ravindra Ganesh[SUP] 6 [/SUP], Sidna Tulledge-Scheitel[SUP] 7 [/SUP], Raymund R Razonable[SUP] 8 [/SUP]
Affiliations
- PMID: 38443438
- PMCID: PMC10914739
- DOI: 10.1038/s41598-024-56195-y
Studies conducted prior to SARS-CoV-2 Omicron demonstrated that sotrovimab and remdesivir reduced hospitalization among high-risk outpatients with mild to moderate COVID-19. However, their effectiveness has not been directly compared. This study examined all high-risk outpatients with mild to moderate COVID-19 who received either remdesivir or sotrovimab at Mayo Clinic during the Omicron BA.1 surge from January to March 2022. COVID-19-related hospitalization or death within 28 days were compared between the two treatment groups. Among 3257 patients, 2158 received sotrovimab and 1099 received remdesivir. Patients treated with sotrovimab were younger and had lower comorbidity but were more likely to be immunocompromised than remdesivir-treated patients. The majority (89%) had received at least one dose of COVID-19 vaccine. COVID-19-related hospitalization (1.5% and 1.0% in remdesivir and sotrovimab, respectively, p = .15) and mortality within 28 days (0.4% in both groups, p = .82) were similarly low. A propensity score weighted analysis demonstrated no significant difference in the outcomes between the two groups. We demonstrated favorable outcomes that were not significantly different between patients treated with remdesivir or sotrovimab.
Keywords: COVID-19; Outcome; Remdesivir; SARS-2-CoV; Sotrovimab.